{"schema_version":"secwatch.filing_event.v1","accession":"0002019410-26-000011","form_type":"8-K","ticker":"CAI","cik":"0002019410","company_name":"Caris Life Sciences, Inc.","filed_at":"2026-02-26T23:59:59+00:00","discovered_at":"2026-05-14T18:02:37.002651+00:00","generated_at":"2026-05-15T23:51:37.641482+00:00","sec_items":["2.02","7.01","9.01"],"event_type":"earnings","sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"confidence":"high","headline":"Caris Q4 net income $82M; FY25 rev $812M (+97%); guides FY26 rev $1.0-1.02B","bullets":["Q4 2025 revenue $292.9M (+125% YoY); net income $82.0M vs loss of $36.9M prior year.","Full year 2025 revenue $812.0M (+97% YoY); net loss narrowed to $68.1M from $281.9M; Adj. EBITDA $137.7M.","Gross margin improved to 75% in Q4 (from 54%) and 66% for FY (from 43%).","FY26 revenue guidance $1.0-1.02B (23-26% growth); molecular profiling rev growth ~21-22%.","Interim readout of Achieve 1 study for Caris Detect MCED test completed; launch expected H1 2026."],"urls":{"canonical":"https://secwatch.observer/filing/0002019410-26-000011","json":"https://secwatch.observer/filing/0002019410-26-000011.json","markdown":"https://secwatch.observer/filing/0002019410-26-000011.md","text":"https://secwatch.observer/filing/0002019410-26-000011.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000011/0002019410-26-000011-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/2019410/000201941026000011/cai-20260226.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T23:51:37.641482+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}